2024
Biologics for Psoriasis
Wride A, Chen G, Spaulding S, Tkachenko E, Cohen J. Biologics for Psoriasis. Dermatologic Clinics 2024, 42: 339-355. PMID: 38796266, DOI: 10.1016/j.det.2024.02.001.Peer-Reviewed Original ResearchConceptsIL-23IL-17ALong-term risk-benefit profileTNF-aLong-term adverse eventsIL-23 inhibitorsTumor necrosis factor-alphaP19 subunit of IL-23Risk-benefit profileSubunit of IL-23TNF-a inhibitorsTreatment of psoriasisNecrosis factor-alphaHigher Psoriasis AreaRates of short-termIL-12/23Psoriasis AreaIL-17FAdverse eventsIL-12IL-17Factor-alphaP19 subunitInjectable biologicsP40 subunit
2022
Trends in the Cost and Utilization of Omalizumab in the Medicare Population: 2013-2017.
Cheraghlou S, Ugwu N, Yu B, Cohen JM. Trends in the Cost and Utilization of Omalizumab in the Medicare Population: 2013-2017. The Yale Journal Of Biology And Medicine 2022, 95: 207-212. PMID: 35782473, PMCID: PMC9235260.Peer-Reviewed Original ResearchProvider-level prescription patterns among dermatologists utilizing injectable biologics in psoriasis treatment
Ugwu N, Cheraghlou S, Feng H, Cohen JM. Provider-level prescription patterns among dermatologists utilizing injectable biologics in psoriasis treatment. Journal Of Dermatological Treatment 2022, 33: 2876-2877. PMID: 35509155, DOI: 10.1080/09546634.2022.2071820.Peer-Reviewed Original ResearchMeSH KeywordsBiological ProductsDermatologistsHumansPractice Patterns, Physicians'PrescriptionsPsoriasis
2020
Psoriasis With Eczematous Features: A Retrospective Clinicopathologic Study.
Noorily AR, Criscito MC, Cohen JM, Brinster NK. Psoriasis With Eczematous Features: A Retrospective Clinicopathologic Study. American Journal Of Dermatopathology 2020, 43: 112-118. PMID: 32618707, DOI: 10.1097/dad.0000000000001711.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultAgedAged, 80 and overBiological ProductsBiopsyDatabases, FactualDermatitis, Allergic ContactEczemaFemaleGlucocorticoidsHumansImmunosuppressive AgentsMaleMiddle AgedPredictive Value of TestsPsoriasisRemission InductionRetrospective StudiesSkinTreatment OutcomeYoung AdultConceptsAllergic contact dermatitisPsoriasis vulgarisClinical characteristicsHistopathological featuresEczematous changesDiagnostic workupSuccessful treatmentContact dermatitisOutcomes of patientsPercent of patientsHalf of patientsRetrospective chart reviewFeatures of psoriasisRetrospective clinicopathologic studyEczematous dermatosesEczematous featuresChart reviewClinicopathologic studyMost patientsSystemic therapyTopical glucocorticoidsHistopathologic featuresChallenging diagnosisClinicopathologic correlationTreatment modalities
2018
Access to injectable biologic medications by medicare beneficiaries: geographic distribution of US dermatologist prescribers
Feng H, Cohen JM, Neimann AL. Access to injectable biologic medications by medicare beneficiaries: geographic distribution of US dermatologist prescribers. Journal Of Dermatological Treatment 2018, 30: 237-239. PMID: 30078341, DOI: 10.1080/09546634.2018.1508819.Peer-Reviewed Original Research